Orlandi Richard R, Kingdom Todd T, Smith Timothy L, Bleier Benjamin, DeConde Adam, Luong Amber U, Poetker David M, Soler Zachary, Welch Kevin C, Wise Sarah K, Adappa Nithin, Alt Jeremiah A, Anselmo-Lima Wilma Terezinha, Bachert Claus, Baroody Fuad M, Batra Pete S, Bernal-Sprekelsen Manuel, Beswick Daniel, Bhattacharyya Neil, Chandra Rakesh K, Chang Eugene H, Chiu Alexander, Chowdhury Naweed, Citardi Martin J, Cohen Noam A, Conley David B, DelGaudio John, Desrosiers Martin, Douglas Richard, Eloy Jean Anderson, Fokkens Wytske J, Gray Stacey T, Gudis David A, Hamilos Daniel L, Han Joseph K, Harvey Richard, Hellings Peter, Holbrook Eric H, Hopkins Claire, Hwang Peter, Javer Amin R, Jiang Rong-San, Kennedy David, Kern Robert, Laidlaw Tanya, Lal Devyani, Lane Andrew, Lee Heung-Man, Lee Jivianne T, Levy Joshua M, Lin Sandra Y, Lund Valerie, McMains Kevin C, Metson Ralph, Mullol Joaquim, Naclerio Robert, Oakley Gretchen, Otori Nobuyoshi, Palmer James N, Parikh Sanjay R, Passali Desiderio, Patel Zara, Peters Anju, Philpott Carl, Psaltis Alkis J, Ramakrishnan Vijay R, Ramanathan Murugappan, Roh Hwan-Jung, Rudmik Luke, Sacks Raymond, Schlosser Rodney J, Sedaghat Ahmad R, Senior Brent A, Sindwani Raj, Smith Kristine, Snidvongs Kornkiat, Stewart Michael, Suh Jeffrey D, Tan Bruce K, Turner Justin H, van Drunen Cornelis M, Voegels Richard, Wang De Yun, Woodworth Bradford A, Wormald Peter-John, Wright Erin D, Yan Carol, Zhang Luo, Zhou Bing
University of Utah, Salt Lake City, UT.
University of Colorado, Denver, CO.
Int Forum Allergy Rhinol. 2021 Mar;11(3):213-739. doi: 10.1002/alr.22741.
I.
BACKGROUND: The 5 years since the publication of the first International Consensus Statement on Allergy and Rhinology: Rhinosinusitis (ICAR-RS) has witnessed foundational progress in our understanding and treatment of rhinologic disease. These advances are reflected within the more than 40 new topics covered within the ICAR-RS-2021 as well as updates to the original 140 topics. This executive summary consolidates the evidence-based findings of the document.
ICAR-RS presents over 180 topics in the forms of evidence-based reviews with recommendations (EBRRs), evidence-based reviews, and literature reviews. The highest grade structured recommendations of the EBRR sections are summarized in this executive summary.
ICAR-RS-2021 covers 22 topics regarding the medical management of RS, which are grade A/B and are presented in the executive summary. Additionally, 4 topics regarding the surgical management of RS are grade A/B and are presented in the executive summary. Finally, a comprehensive evidence-based management algorithm is provided.
This ICAR-RS-2021 executive summary provides a compilation of the evidence-based recommendations for medical and surgical treatment of the most common forms of RS.
一、
背景：自第一份《变应性鼻炎和鼻-鼻窦炎国际共识声明》（ICAR-RS）发表以来的5年里，我们在鼻科疾病的认识和治疗方面取得了基础性进展。这些进展反映在ICAR-RS-2021涵盖的40多个新主题以及对原140个主题的更新中。本执行摘要汇总了该文件基于证据的研究结果。
ICAR-RS以基于证据的综述及建议（EBRR）、基于证据的综述和文献综述的形式呈现了180多个主题。本执行摘要总结了EBRR部分最高级别的结构化建议。
ICAR-RS-2021涵盖了22个关于鼻-鼻窦炎药物治疗的主题，这些主题为A级/B级，并在执行摘要中呈现。此外，4个关于鼻-鼻窦炎手术治疗的主题为A级/B级，并在执行摘要中呈现。最后，提供了一个全面的基于证据的管理算法。
本ICAR-RS-2021执行摘要汇总了针对最常见形式鼻-鼻窦炎的药物和手术治疗的基于证据的建议。
